Amgen – Amgen (AMGN) to Release Quarterly Earnings on Tuesday
Amgen (NASDAQ:AMGN) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, February 2nd. Analysts expect the company to announce earnings of $3.38 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Monday, November 2nd. The medical research company reported $4.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.75 by $0.62. Amgen had a net margin of 29.42% and a return on equity of 95.55%. The firm had revenue of $6.42 billion for the quarter, compared to analyst estimates of $6.38 billion. On average, analysts expect Amgen to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.
Shares of NASDAQ:AMGN opened at $257.10 on Tuesday. The firm has a fifty day moving average of $233.69 and a two-hundred day moving average of $238.33. The firm has a market capitalization of $149.68 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. Amgen has a 12-month low of $177.05 and a 12-month high of $264.97. The company has a quick ratio of 1.88, a current ratio of 2.28 and a debt-to-equity ratio of 3.12.
The business also recently declared a quarterly dividend, which will be paid on Monday, March 8th. Stockholders of record on Monday, February 15th will be paid a $1.76 dividend. The ex-dividend date of this dividend is Thursday, February 11th. This is an increase from Amgen’s previous quarterly dividend of $1.60. This represents a $7.04 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s dividend payout ratio is 43.18%.
A number of brokerages have commented on AMGN. Truist upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Monday, October 12th. SVB Leerink boosted their price target on Amgen from $243.00 to $253.00 and gave the company a “market perform” rating in a research note on Wednesday, December 9th. Barclays cut their price objective on shares of Amgen from $250.00 to $242.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. Morgan Stanley lifted their target price on shares of Amgen from $276.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, January 19th. Finally, Bank of America dropped their price target on shares of Amgen from $275.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and a consensus target price of $254.48.
In related news, Director R Sanders Williams sold 250 shares of Amgen stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $242.40, for a total transaction of $60,600.00. Following the transaction, the director now owns 4,909 shares of the company’s stock, valued at approximately $1,189,941.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 13th. The shares were sold at an average price of $235.99, for a total transaction of $235,990.00. Following the transaction, the director now owns 16,805 shares of the company’s stock, valued at approximately $3,965,811.95. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
See Also: What is Blockchain?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]